On March 26, 2026, Lunai Bioworks, Inc. (NASDAQ: LNAI) announced a significant strategic transaction involving the acquisition of blood-brain barrier (BBB) delivery technology and central nervous system (CNS) Alzheimer’s drug assets from Clemann Group, SAS. This acquisition is structured as a $20 million investment in the form of Series B Convertible Preferred Stock, with a fixed conversion price of $1.50 per share, subject to a 19.9% beneficial ownership limitation. The transaction aims to enhance Lunai's capabilities in developing next-generation treatments for CNS disorders, particularly Alzheimer's disease, by facilitating the effective transport of therapeutics across the blood-brain barrier. The technology allows compounds to remain inactive in the body until they reach the brain, targeting pathways associated with neurological diseases. CEO David Weinstein emphasized the importance of this acquisition, stating it represents a step-change in Lunai's capabilities, combining precise biological target identification with a validated delivery mechanism. The transaction is expected to strengthen Lunai's CNS Alzheimer’s pipeline and expand its ability to develop treatments across a broader range of CNS disorders. The closing of the transaction is subject to customary conditions, including board approval and compliance with Nasdaq listing requirements. This strategic move is anticipated to have a noticeable positive effect on Lunai's stock price as it positions the company for future growth in the competitive biopharmaceutical market.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.